Associated Papers
CldU sensitizes BRCA2 reverse-mutated cells to PARP inhibitors.
Zouggari N et al.
Frontiers in Oncology, 2025
Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM.
Ito F et al.
Nature Communications, 2024
Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.
Xu Y et al.
Cell Reports, 2023
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Stordal B et al.
Molecular Oncology, 2013
The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
Ng CK et al.
The Journal of Pathology, 2012
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Sakai W et al.
Cancer Research, 2009
Select a paper to view details